- The new drug would be sold under the brand name Hemlibra in the country
- It represents an entirely new way to manage Hemophilia A and reviews the standard of care
Roche Pharmaceuticals, the Swiss multinational healthcare company, has reportedly announced that it has introduced Emicizumab under the brand name Hemlibra in India. As per trusted sources, Emicizumab is aimed at preventive treatment of Hemophilia A, an inherited ailment in which a person’s blood does not clot correctly.
Roche issued a statement in which it noted that all the existing prophylactic treatment options for people with emophilia A with factor VIII inhibitors need intravenous infusions numerous times per week. Hemlibra is the very first weekly subcutaneous prophylaxis drug which reduces and prevents the frequency of bleeding episodes and enhances the quality of patient’s life, noted the statement.
According to The Hindu Business Line, the new drug shows a completely new way to manage Hemophilia A and it also reviews the current standard of healthcare care in the country.
Chief Purpose Officer of Roche Pharma India, Lara Bezerra was reportedly quoted saying that the launch of Emicizumab (Hemlibra) is an important milestone in the treatment of Hemophilia A in India. The launch of the new drug affirms the commitment of the company to bring its advanced medicines to patients in India as soon as possible, Bezerra further added.
For the uninitiated, Hemophilia A is an inherited, serious ailment in which a person’s blood does not clot appropriately, leading to frequent, spontaneous, and uncontrolled bleeding.
Reportedly, Hemlibra has been approved by numerous regulatory agencies across the globe in the past and is now also approved and available in India. However, Roche Pharma has not disclosed the price at which it plans to sell the medicine in the nation, cite sources.